<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Breast Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Int J Breast Cancer</journal-id><journal-id journal-id-type="publisher-id">IJBC</journal-id><journal-title-group><journal-title>International Journal of Breast Cancer</journal-title></journal-title-group><issn pub-type="ppub">2090-3170</issn><issn pub-type="epub">2090-3189</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5086358</article-id><article-id pub-id-type="doi">10.1155/2016/2469523</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9807-4304</contrib-id><name><surname>Pesaran</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Karam</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Huether</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Farber-Katz</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Chamberlin</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Chong</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>LaDuca</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6099-5124</contrib-id><name><surname>Elliott</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA</aff><author-notes><corresp id="cor1">*T. Pesaran: <email>tpesaran@ambrygen.com</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Zsuzsanna Kahán </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>2469523</elocation-id><history><date date-type="received"><day>4</day><month>6</month><year>2016</year></date><date date-type="rev-recd"><day>4</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 T. Pesaran et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Genetic testing for hereditary breast cancer is an integral part of individualized care in the new era of precision medicine. </plain></SENT>
<SENT sid="3" pm="."><plain>The accuracy of an assay is reliant on not only the technology and bioinformatics analysis utilized but also the experience and infrastructure required to correctly classify genetic variants as disease-causing. </plain></SENT>
<SENT sid="4" pm="."><plain>Interpreting the clinical significance of germline variants identified by hereditary cancer testing is complex and has a significant impact on the management of patients who are at increased cancer risk. </plain></SENT>
<SENT sid="5" pm="."><plain>In this review we give an overview of our clinical laboratory's integrated approach to variant assessment. </plain></SENT>
<SENT sid="6" pm="."><plain>We discuss some of the nuances that should be considered in the assessment of genomic variants. </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, we highlight lines of evidence such as functional assays and structural analysis that can be useful in the assessment of rare and complex variants. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="8" pm="."><plain>1. </plain></SENT>
<SENT sid="9" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>The landscape of genetic testing for hereditary breast cancer susceptibility has changed drastically with the application of massively parallel sequencing based tests in clinical diagnostics. </plain></SENT>
<SENT sid="11" pm="."><plain>Clinical genomic laboratories are performing an increasing number of massively parallel sequencing assays for cancer predisposition genes [1], which has led to an intensified application of these assays in clinical and research settings [2]. </plain></SENT>
<SENT sid="12" pm="."><plain>Breast cancer gene panels and exome sequencing generate vast amounts of genetic alteration data, thereby presenting a significant challenge to determine which variants are responsible for the disease or phenotype. </plain></SENT>
<SENT sid="13" pm="."><plain>Multigene breast cancer panels in particular have gained in popularity over the past few years and are now routinely ordered by genetics, oncology, and breast surgical clinics. </plain></SENT>
<SENT sid="14" pm="."><plain>These tests allow for simultaneous analysis of numerous cancer genes that, when mutated, can have a significant impact on cancer risk stratification and management [3]. </plain></SENT>
<SENT sid="15" pm="."><plain>A major component of clinical molecular diagnostic testing is accurate assessment and interpretation of genetic variants. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>Ambry Genetics' BreastNext Cancer panel analyzes 17 genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, and TP53) by massively parallel sequencing of all coding exons and a minimum of 5 base pairs into the flanking 5′ and 3′ ends of all introns and untranslated regions. </plain></SENT>
<SENT sid="17" pm="."><plain>In addition, clinically significant intronic mutations beyond 5 base pairs and the promoter region of PTEN (c.-1300 to c.-745) are always sequenced and reported. </plain></SENT>
<SENT sid="18" pm="."><plain>Sequencing is conducted on the Illumina HiSeq2500 or NextSeq using 150 bp paired-end conditions as described in the manufacturer's standard workflow (Illumina). </plain></SENT>
<SENT sid="19" pm="."><plain>After initial data processing, all clinical samples had to pass minimum thresholds to be included in the analysis. </plain></SENT>
<SENT sid="20" pm="."><plain>The three parameters were as follows: mean base calling quality score is greater than 30, the percentage of passes that reached over 30 had to be 75% overall, and the percentage of perfectly matched indexes needed to be greater than 85%. </plain></SENT>
<SENT sid="21" pm="."><plain>For each gene, a minimum coverage of 20x is required for candidate variants to be called. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>In an effort to help standardize the interpretation and reporting of genetic testing results, organizations such as the American College of Medical Genetics and Genomics (ACMG), Association for Molecular Pathology (AMP), and the International Agency for Research and Cancer (IARC) have proposed criteria for the interpretation and reporting of sequence variants [7–9]. </plain></SENT>
<SENT sid="23" pm="."><plain>These criteria weigh multiple lines of evidence to categorize variants under a five-tier classification algorithm using terms such as pathogenic (P), variant, likely pathogenic (VLP), variant of unknown significance (VUS), variant, likely benign (VLB), and benign (B) to indicate the likelihood of association with disease. </plain></SENT>
<SENT sid="24" pm="."><plain>Per ACMG guidelines, the term “likely” refers to a classification tier that equates to a &gt;90% likelihood of a variant being disease-causing or benign [7, 8]. </plain></SENT>
<SENT sid="25" pm="."><plain>Recently the clinical utility of the ACMG guidelines was demonstrated in a cohort of individuals undergoing sequencing for inherited cancer risk [10]. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>While the ACMG guidelines provide a basic framework for variant assessment, gene and syndrome-specific factors such as penetrance, prevalence, inheritance pattern, disease mechanism, and protein structure and function need to be considered. </plain></SENT>
<SENT sid="27" pm="."><plain>In addition, when considering the phenotype of the patients in which a variant is identified, one must take into account the prevalence of the disease and how the patients are ascertained to account for potential phenocopies. </plain></SENT>
<SENT sid="28" pm="."><plain>For example, many genes on hereditary breast cancer panels are considered to be moderate penetrance and are associated with a 2- to 5-fold increased breast cancer risk. </plain></SENT>
<SENT sid="29" pm="."><plain>Given the relatively high prevalence of breast cancer (1/8 women in the US), traditional segregation methods are confounded by phenocopies and are even more difficult to employ with genes that have reduced penetrance. </plain></SENT>
<SENT sid="30" pm="."><plain>These confounders indicate that these genes require large numbers of segregation events to provide meaningful results. </plain></SENT>
<SENT sid="31" pm="."><plain>Consideration should also be given to gene-specific factors such as frequency of germline and somatic de novo alterations, additional tests in tumors such as loss of heterozygosity studies, variation in nonsense-mediated decay, and alternate splicing. </plain></SENT>
<SENT sid="32" pm="."><plain>For example, in genes such as TP53 and PTEN, germline de novo variants are known to be a relatively common cause of disease [11, 12]. </plain></SENT>
<SENT sid="33" pm="."><plain>However, with breast cancer genes such as ATM, CHEK2, and PALB2, the de novo rate is unknown. </plain></SENT>
<SENT sid="34" pm="."><plain>This is confounded by the fact that breast cancer is a common disease and one cannot infer if the de novo event in these genes directly correlates with disease or occurred by chance. </plain></SENT>
<SENT sid="35" pm="."><plain>In addition, although somatic de novo data is available for some genes [13] its incorporation into germline variant analysis has yet to be standardized and will need to be performed on a gene-by-gene basis. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>Consortia such as the Evidence Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) have demonstrated the power of a collaborative approach to variant assessment and have made great strides in the reclassification of VUS in breast cancer genes as pathogenic or benign. </plain></SENT>
<SENT sid="37" pm="."><plain>However even these groups are limited by the rate at which data is accumulated. </plain></SENT>
<SENT sid="38" pm="."><plain>Open-access databases such as ClinVar and the Leiden Open (source) Variant Database (LOVD) can be useful in identifying additional cases or publications related to a variant. </plain></SENT>
<SENT sid="39" pm="."><plain>These databases have also helped standardize the interpretation of variants between laboratories by identifying discrepancies in classifications. </plain></SENT>
<SENT sid="40" pm="."><plain>Collaborative efforts by clinical laboratories including Ambry Genetics, GeneDx, University of Chicago, and Laboratory for Molecular Medicine have resulted in the sharing of internal data consisting of segregation and cooccurrences with mutations in the same gene or other genes and de novo observations have led to the resolution of 78% of clinically actionable differences (VUS versus VLP/mutation) and 92% of VUS versus likely benign/benign differences (internal data). </plain></SENT>
<SENT sid="41" pm="."><plain>Despite these efforts, one of the challenges faced by molecular laboratories and clinicians is that many genetic variants are very rare and do not have enough published data to be classified beyond VUS. </plain></SENT>
<SENT sid="42" pm="."><plain>We present here our laboratory's integrated approach to variant assessment and review tools used to assess the impact of variants on protein function. </plain></SENT>
</text></p></sec></SecTag><sec id="sec2"><title><text><SENT sid="43" pm="."><plain>2. </plain></SENT>
<SENT sid="44" pm="."><plain>Integrated Approach to Variant Assessment </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>Ambry Genetics has developed and implemented an integrated approach to variant assessment (Table 1) that encompasses a five-tier variant classification algorithm similar to those presented by ACMG and IARC. </plain></SENT>
<SENT sid="46" pm="."><plain>Although the foundation of Ambry Genetics' classification algorithm is based on the ACMG guidelines, we have adopted stringent thresholds similar to those proposed by the IARC, where “likely” refers to a &gt;95% confidence of a variant being disease-causing or benign [9]. </plain></SENT>
<SENT sid="47" pm="."><plain>In this algorithm, both pathogenic and likely pathogenic variants are interpreted as clinically actionable with recommendations for medical management and family member testing. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Ambry Genetics' algorithm incorporates multiple lines of evidence aimed at assessing both the impact of the variant on the protein and the pathogenicity of the variant in relation to a disease phenotype (Figure 1 and Table 2). </plain></SENT>
<SENT sid="49" pm="."><plain>These lines of evidence are weighted as stand-alone (categories A and F), strong (categories B and D), or supportive (categories C and E) and when combined as described in Table 1, they can lead to a classification of likely benign, benign, likely pathogenic, or pathogenic. </plain></SENT>
<SENT sid="50" pm="."><plain>When the evidence is limited or conflicting, the variants remain classified as VUS. </plain></SENT>
<SENT sid="51" pm="."><plain>Lines of evidence such as its location, structure-function, and functional and RNA studies reflect the functional impact on the mRNA or protein. </plain></SENT>
<SENT sid="52" pm="."><plain>Evolutionary conservation, in silico models such as Polyphen and SIFT, and general population frequency reflect fitness, that is, reproductive success and survival as measured by a lack of allelic diversity. </plain></SENT>
<SENT sid="53" pm="."><plain>The observed phenotype in variant carriers and the cosegregation of the variant with disease and the cooccurrence with other pathogenic variants reflect the pathogenicity of the variant (Figure 1). </plain></SENT>
<SENT sid="54" pm="."><plain>Some of this evidence is readily available via databases such as allele frequency data in the Exome Aggregation Consortium (ExAC) or the data in published literature [14]. </plain></SENT>
<SENT sid="55" pm="."><plain>However published literature generally contains data for common variants and the data supporting pathogenicity for rare variants is scarce and frequently only available internally. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>For most genes on breast cancer panels, computational data from in silico models, evolutionary conservation, and protein structural analysis are readily available. </plain></SENT>
<SENT sid="57" pm="."><plain>Population frequency data has been accumulating at a fast pace due to major contributions from 1000 Genomes, NHLBI Exome Sequencing Project (ESP), and ExAC. </plain></SENT>
<SENT sid="58" pm="."><plain>These data have had a significant impact on the identification of benign variants at high frequencies that are too frequent to be pathogenic based on disease incidence alone, particularly for historically understudied ethnic groups. </plain></SENT>
<SENT sid="59" pm="."><plain>For breast cancer genes, this threshold has been conservatively set at an allele frequency of 1% in large population cohorts if used as a stand-alone line of evidence supporting benign classification (Table 1, category F). </plain></SENT>
<SENT sid="60" pm="."><plain>Careful consideration of population cohort size is needed to attain a high confidence (lower 95% CI is above 1% with p value &lt;0.05) that the frequency is above 1%. </plain></SENT>
<SENT sid="61" pm="."><plain>For example, with a cohort of 60,000 alleles, an allele frequency of 1.08% is sufficient (lower 95% CI = 1.01%; p = 0.0244) whereas for a cohort of 1000 alleles, an allele frequency of 1.70% (lower 95% CI = 1.15%; p = 0.013) is needed to be 95% confident; the allele frequency is above 1%. </plain></SENT>
</text></p><p><text><SENT sid="62" pm="."><plain>Although patient phenotype, cooccurrence, and cosegregation data can be found in the published literature, many laboratories also curate internal data for use in variant classification. </plain></SENT>
<SENT sid="63" pm="."><plain>A patient's clinical and family history can be difficult to use as a line of evidence in a clinical laboratory setting due to ascertainment bias. </plain></SENT>
<SENT sid="64" pm="."><plain>However, when a variant in a gene associated with a rare disorder (less than 1/2000) is identified in multiple individuals meeting classic clinical criteria and never in large control populations or population cohorts these data can be used as evidence towards pathogenicity. </plain></SENT>
<SENT sid="65" pm="."><plain>This is most informative in patients who have undergone genetic testing on large multigene panel tests in which all the known genes associated with a disorder have been ruled out. </plain></SENT>
<SENT sid="66" pm="."><plain>However, when defining classic clinical criteria we use very strict guidelines and exclude common diseases such as breast cancer. </plain></SENT>
<SENT sid="67" pm="."><plain>For example, when assessing a TP53 variant, the phenotype is considered strong if the patient meets classic Li-Fraumeni syndrome criteria: a proband with sarcoma diagnosed before 45 years, a first-degree relative with any cancer before 45 years, and a second-degree relative with any cancer before age 45 years or a sarcoma at any age [15]. </plain></SENT>
<SENT sid="68" pm="."><plain>For common diseases and moderate penetrance genes Bayesian analyses that require larger phenotype data sets are used [16]. </plain></SENT>
<SENT sid="69" pm="."><plain>Historically, in vitro studies were predominantly found in the published literature. </plain></SENT>
<SENT sid="70" pm="."><plain>However due to the rapid accumulation of rare variants, clinical laboratories such as Ambry Genetics are implementing validated internal functional studies such as splicing and homology-directed DNA break repair (HDR) assays that can be incorporated into variant classification algorithms. </plain></SENT>
</text></p></sec><sec id="sec3"><title><text><SENT sid="71" pm="."><plain>3. </plain></SENT>
<SENT sid="72" pm="."><plain>Functional Lab </plain></SENT>
</text></title><p><text><SENT sid="73" pm="."><plain>Many variants are classified as VUS because their functional impact either is poorly understood or has not yet been investigated. </plain></SENT>
<SENT sid="74" pm="."><plain>These variants include missense and splicing alterations in tumor suppressor genes that require loss of function to manifest a disease [7]. </plain></SENT>
<SENT sid="75" pm="."><plain>Clinical genomic laboratories have traditionally relied on evidence from published literature to establish the impact of a variant on gene expression or protein function [7]. </plain></SENT>
<SENT sid="76" pm="."><plain>There are several limitations to this approach, including publication bias, difficulties with promptly obtaining additional information about results and protocols, and lack of published evidence for a specific alteration. </plain></SENT>
<SENT sid="77" pm="."><plain>One potential solution is for clinical genomic laboratories to implement a “functional lab” that can generate assays with high sensitivity and specificity (&gt;99%) and provide unbiased molecular evidence to elucidate the functional impact of a VUS (Figure 2). </plain></SENT>
<SENT sid="78" pm="."><plain>As an example of a convincingly validated assay, Guidugli and colleagues determined the sensitivity of their homology-directed DNA break repair (HDR) functional assay to be 100% (95% confidence interval (CI): 75.3%–100%) and the specificity to be 100% (95% CI: 81.5%–100%) [17]. </plain></SENT>
</text></p><sec id="sec3.1"><title><text><SENT sid="79" pm="."><plain>3.1. </plain></SENT>
<SENT sid="80" pm="."><plain>RNA Studies for Splicing VUS </plain></SENT>
</text></title><p><text><SENT sid="81" pm="."><plain>While some splicing variants, such as canonical ±1 or 2 splice sites, are often assumed to disrupt gene function by leading to the reduced expression of the abnormal allele due to nonsense-mediated decay (NMD) [18] or abnormal protein truncations [19], comprehensive evaluation of splicing alterations is essential for accurate clinical interpretation. </plain></SENT>
<SENT sid="82" pm="."><plain>For canonical splice site ±1 and 2 variants, one must also consider the possibility of an in-frame deletion/insertion, which could retain the critical regions of the protein and hence lead to a mild, neutral, or gain-of-function effect. </plain></SENT>
<SENT sid="83" pm="."><plain>In addition, variants that are predicted to impact splicing but that are not located at the canonical sites (±1 and 2) require additional strong evidence (see details in Section 2) to be classified as pathogenic or benign [7]. </plain></SENT>
<SENT sid="84" pm="."><plain>Bioinformatics software has been developed to predict putative splice sites [20]. </plain></SENT>
<SENT sid="85" pm="."><plain>In general, these in silico tools are more sensitive (~90–100%) than being specific (~60–80%) when predicting the impact of a variant on splicing [21, 22]. </plain></SENT>
<SENT sid="86" pm="."><plain>However, by nature in silico tools can only provide supporting evidence which restricts their use [7]. </plain></SENT>
<SENT sid="87" pm="."><plain>Consequently, data from RNA splicing assays, designed to provide quantitative and qualitative characterization of transcripts, are usually necessary to evaluate the pathogenicity of these variants. </plain></SENT>
<SENT sid="88" pm="."><plain>Since published RNA data is not available for every variant, clinical genomic laboratories can more accurately classify splicing alterations by implementing their own RNA protocols and assays to provide accurate classification of splicing alterations. </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>Reliability, in which an assay yields the same results in repeated trials, is a key issue when implementing mRNA assays in a clinical functional lab for evaluation of VUS. </plain></SENT>
<SENT sid="90" pm="."><plain>To improve reliability, the ENIGMA consortium conducted a multicenter investigation to compare mRNA splicing assay protocols used by its members [23]. </plain></SENT>
<SENT sid="91" pm="."><plain>The consortium provided several recommendations for best practices in clinical testing of splicing alterations, including the standardization of protocols and the use of analytically sensitive detection methods [23]. </plain></SENT>
<SENT sid="92" pm="."><plain>Of the detection methods evaluated, capillary electrophoresis (CE) was shown to yield the highest analytic sensitivity. </plain></SENT>
<SENT sid="93" pm="."><plain>However, a major limitation of CE is its inability to harvest and subsequently perform sequence analysis of the RT-PCR product. </plain></SENT>
<SENT sid="94" pm="."><plain>In order to perform sequence analysis and full characterization of alternatively spliced transcripts, the consortium concluded that cloning single PCR products into a vector system is a useful alternative for isolating single transcripts for sequencing, which improves sensitivity over band excision and sequencing alone. </plain></SENT>
<SENT sid="95" pm="."><plain>Even in cases that appear straightforward, the consortium recommends using in vivo, in vitro, and clinical analysis to predict with 99% likelihood that a variant is benign or pathogenic [23]. </plain></SENT>
<SENT sid="96" pm="."><plain>For example, although most canonical splice site variants are considered a priori to be at least likely pathogenic, the presence of naturally occurring alternative splicing that mimics a pathogenic alteration and results in a similar impact on splicing (e.g., exon skipping) needs to be carefully evaluated, as it may result in diminished pathogenicity. </plain></SENT>
<SENT sid="97" pm="."><plain>Care must be taken to determine whether a transcript is present in normal controls. </plain></SENT>
<SENT sid="98" pm="."><plain>As the functional lab obtains more data on each gene, a more accurate picture of splicing patterns will emerge, thereby leading to improved classification of splice site variations. </plain></SENT>
</text></p></sec><sec id="sec3.2"><title><text><SENT sid="99" pm="."><plain>3.2. </plain></SENT>
<SENT sid="100" pm="."><plain>Functional Assays for Missense VUS </plain></SENT>
</text></title><p><text><SENT sid="101" pm="."><plain>Missense alterations with no impact on splicing can be evaluated by utilizing wet lab assays or experimental structure data. </plain></SENT>
<SENT sid="102" pm="."><plain>While functional studies can be a powerful tool in support of pathogenicity, not all functional studies accurately predict impacts on gene or protein function. </plain></SENT>
<SENT sid="103" pm="."><plain>For this reason ACMG/AMP provides recommendations for assessing the validity of functional assays, in order to confirm that the functional assay accurately measures a function that leads to disease [7]. </plain></SENT>
<SENT sid="104" pm="."><plain>One must consider how closely the functional assay reflects the biological environment. </plain></SENT>
<SENT sid="105" pm="."><plain>This is important when deciding whether to test patient samples or to perform in vitro assays. </plain></SENT>
<SENT sid="106" pm="."><plain>It is important to consider the known biological functions of the protein, while also examining whether those functions actually contribute to tumorigenicity. </plain></SENT>
<SENT sid="107" pm="."><plain>For example, many functional assays have been developed to interrogate BRCA1 VUS [24]. </plain></SENT>
<SENT sid="108" pm="."><plain>Some assays focus on the known DNA repair functions of BRCA1, such as the HDR assay [25, 26] and the radiation resistance assay [27]. </plain></SENT>
<SENT sid="109" pm="."><plain>Others examine BRCA1 localization [28, 29] and the ability of cells with BRCA1 variants to generate Rad51 foci [30, 31] in the presence of DNA damage as surrogates for BRCA1 function. </plain></SENT>
<SENT sid="110" pm="."><plain>Additional assays focus on one functional component of BRCA1 instead of the full protein, including the transcription activation assay, which employs the C-terminal BRCT domains, and the ubiquitin ligase assay, which utilizes the N-terminal region [32–35]. </plain></SENT>
<SENT sid="111" pm="."><plain>These two assays are limited by their inability to account for effects of the entire protein, and others have noted that certain variants that lost ubiquitin ligase activity were not classified as pathogenic by genetic studies [36, 37]. </plain></SENT>
<SENT sid="112" pm="."><plain>Similarly, protein or peptide binding assays may resolve the ability of a variant to bind to a protein target in vitro, but these data should be incorporated into a multifactorial model that takes into account other functional in vivo data [38, 39]. </plain></SENT>
<SENT sid="113" pm="."><plain>In addition, validation data that assess the analytical performance of the assay and account for specimen integrity are important factors to consider when implementing functional assays in a functional clinical genomic laboratory and in using these results in classification of variants [7]. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>To investigate the effect of missense variants on BRCA1 function, Lu et al. tested 68 missense variants using an in vitro HDR assay [26]. </plain></SENT>
<SENT sid="115" pm="."><plain>The analysis showed that the HDR defective or partial defective missense variants from the BRCT domain are positioned either in the center of the structure or on the surface responsible for protein-protein interactions, while the HDR-WT variants from the BRCT domain were surface exposed or partially surface exposed variants [26]. </plain></SENT>
<SENT sid="116" pm="."><plain>This highlights the complexity of interpreting missense germline variants, indicating that an integrated approach, by compiling the results of functional assays, structure evaluation, and analysis of clinical parameters, should identify the most functionally and clinically relevant alterations. </plain></SENT>
</text></p></sec><sec id="sec3.3"><title><text><SENT sid="117" pm="."><plain>3.3. </plain></SENT>
<SENT sid="118" pm="."><plain>Analysis of Insertion Breakpoints for Gross Duplications </plain></SENT>
</text></title><p><text><SENT sid="119" pm="."><plain>Most gross deletions in high-risk cancer genes, larger than 3~5 megabases, fall within microarray reporting guidelines and are reported as deleterious [38, 39]; however, without breakpoint information gross duplications are mostly reported as VUS. </plain></SENT>
<SENT sid="120" pm="."><plain>While array comparative genomic hybridization (aCGH) is a method used in cancer research for the detection of gross chromosomal aberrations in cancer genes, it cannot accurately determine the exact genomic breakpoints of the amplification [40–43]. </plain></SENT>
<SENT sid="121" pm="."><plain>To map the exact insertion breakpoints, paired-end high throughput sequencing can be used. </plain></SENT>
<SENT sid="122" pm="."><plain>Gross genomic amplifications may occur as a tandem duplication within the cancer gene itself, resulting in a novel function, or as a nontandem duplication inserted in a novel location of the genome. </plain></SENT>
<SENT sid="123" pm="."><plain>Therefore, identifying the exact breakpoints of tandem duplications in high-risk cancer genes can lead to VUS being reclassified as likely pathogenic or likely benign. </plain></SENT>
</text></p><p><text><SENT sid="124" pm="."><plain>To identify the exact breakpoints of tandem duplications, Ambry Genetics is currently utilizing the paired-end sequencing method to further characterize gross duplications. </plain></SENT>
<SENT sid="125" pm="."><plain>Probe sets are designed to capture the target regions with the suggested breakpoints identified by aCGH. </plain></SENT>
<SENT sid="126" pm="."><plain>Captured DNA is then sequenced by paired-end massively parallel sequencing and mapped to the human genome. </plain></SENT>
<SENT sid="127" pm="."><plain>The Ambry Genetics pipeline identifies read pairs that are in the wrong orientation, indicating a tandem duplication (Figure 3(a)). </plain></SENT>
<SENT sid="128" pm="."><plain>Clusters of read pairs with soft clipping that span breakpoints can indicate rearrangement breakpoints down to the exact coordinates (Figure 3(b)). </plain></SENT>
<SENT sid="129" pm="."><plain>As an example, an exon 11 duplication in BRCA1 previously classified as VUS can be reclassified as likely pathogenic if the breakpoint is identified to cause a frameshift in the gene (Figure 3). </plain></SENT>
</text></p></sec></sec><SecTag type="METHODS"><sec id="sec4"><title><text><SENT sid="130" pm="."><plain>4. </plain></SENT>
<SENT sid="131" pm="."><plain>Computational Structural Analysis </plain></SENT>
</text></title><p><text><SENT sid="132" pm="."><plain>Computational structural algorithms offer a unique solution for assessing a variant's impact on protein function in that they are faster than experimental studies and often use data from many scientific disciplines [44]. </plain></SENT>
<SENT sid="133" pm="."><plain>However, the quality of the information provided by computational analyses varies depending on the information source. </plain></SENT>
<SENT sid="134" pm="."><plain>For instance, primary sequence analyses using evolutionary tools can identify the likely impact of a variant. </plain></SENT>
<SENT sid="135" pm="."><plain>By comparing an altered human sequence to proteins with a similar primary sequence or related structural shape, the fitness of the variant can be predicted based on the variability of that position and other aspects such as the chemical similarity of the wild type and variant amino acids. </plain></SENT>
<SENT sid="136" pm="."><plain>Ambry Genetics relies on multiple tools, including the “Sorting Intolerant from Tolerant” (SIFT) and Polyphen2 programs [40]. </plain></SENT>
<SENT sid="137" pm="."><plain>We use the consensus of two programs, usually SIFT and Polyphen2 where applicable, and consider only concordant results as a line of evidence. </plain></SENT>
<SENT sid="138" pm="."><plain>If only one program is applicable such as Provean [45] with indels we incorporate predictions from the single program with conservative thresholds determined by analysis of our internal data. </plain></SENT>
<SENT sid="139" pm="."><plain>Alternatively, analyses of the secondary and tertiary structures of the protein increase the reliability of interpretation. </plain></SENT>
<SENT sid="140" pm="."><plain>The most reliable computational algorithms focus on biophysics methods which are more oriented towards direct simulation of the physical processes occurring in a protein [46–48]. </plain></SENT>
<SENT sid="141" pm="."><plain>In many regards, computational methods are the most diverse in the range of properties that they can quantify; however, they come at the expense of computational requirements and speed with which accurate properties can be derived. </plain></SENT>
<SENT sid="142" pm="."><plain>One of the most common and easily identified sources of disruption induced by a variant is the influence on protein stability [46, 47, 49–51]. </plain></SENT>
<SENT sid="143" pm="."><plain>Protein stability can be affected in multiple ways, such as misfolding or unfolding of the protein structure, which commonly results in either loss of function or premature degradation and haploinsufficiency. </plain></SENT>
<SENT sid="144" pm="."><plain>As an example, protein stability has been used by Karchin et al. to generate a predictive tool for the likelihood of the effect of an alteration in the breast cancer gene BRCA2 [52]. </plain></SENT>
<SENT sid="145" pm="."><plain>There are other significant ways that variants exert their pathogenic effect which can be described through structure. </plain></SENT>
<SENT sid="146" pm="."><plain>For instance, a variant may not significantly affect the resting state structure of the protein but rather affect the movement of the protein in the course of its function. </plain></SENT>
<SENT sid="147" pm="."><plain>It may impact its binding with other target proteins or substrates or it may induce aggregation [47, 48]. </plain></SENT>
<SENT sid="148" pm="."><plain>Detailed understanding of biophysical principles illuminated through structure is crucial to evaluate and interpret the impact of alterations. </plain></SENT>
</text></p></sec></SecTag><sec id="sec5"><title><text><SENT sid="149" pm="."><plain>5. </plain></SENT>
<SENT sid="150" pm="."><plain>Tertiary and Quaternary Sequence of Breast Cancer Genes </plain></SENT>
</text></title><p><text><SENT sid="151" pm="."><plain>The use of biophysical methods to predict the impact of a variant on a protein often requires the availability of structures for the target gene or benefits significantly from it. </plain></SENT>
<SENT sid="152" pm="."><plain>Among the 17 genes represented in the BreastNext Cancer panel, there are a total of 247 experimentally derived structures, tabulated per gene in the PDBs (Protein DataBank files) column of Table 2, using either Nuclear Magnetic Resonance Imaging (NMR) or X-ray crystallographic methods [5, 53]. </plain></SENT>
<SENT sid="153" pm="."><plain>The coverage described above corresponds to the total range of residues covered by all experimental measurements divided by the total length of the protein. </plain></SENT>
<SENT sid="154" pm="."><plain>While there are notable exceptions where no experimental structures have been determined, the majority of the genes have been partially and in the case of TP53 completely elucidated experimentally. </plain></SENT>
<SENT sid="155" pm="."><plain>The structure of TP53 is highly ordered throughout the protein, allowing for complete measurement of one low-energy form; however some proteins in this set such as BRCA1 and BRCA2 are composed of regions which have no characteristic fixed structure. </plain></SENT>
<SENT sid="156" pm="."><plain>The ordered regions within the structured protein, such as in the N (Really Interesting New Gene, i.e., RING, domain) and C terminus (BRCA1 C Terminus, i.e., BRCT, repeats) of BRCA1, offer higher quality means to define domain boundaries. </plain></SENT>
<SENT sid="157" pm="."><plain>These can be analyzed as a folded functional unit rather than through conservation techniques that are used in the Protein Families (Pfam) database [54] or using meta predictors such as InterPro [55]. </plain></SENT>
<SENT sid="158" pm="."><plain>The structural coverage for the genes in Table 2 does not take into account that long stretches of some proteins have little intrinsic globular structure, so the numbers can be seen as a very conservative estimate of the range of available residues covered. </plain></SENT>
<SENT sid="159" pm="."><plain>In addition, there remain some proteins, such as ATM or NBN, where no or low-resolution structures have been experimentally measured [5, 6]. </plain></SENT>
<SENT sid="160" pm="."><plain>For these systems, structural analysis incorporates the use of homology models built on the structures of known related proteins. </plain></SENT>
<SENT sid="161" pm="."><plain>This significantly increases the effective range of structural coverage and the insights available. </plain></SENT>
</text></p><p><text><SENT sid="162" pm="."><plain>Disruption in the folding of a domain in a protein by a missense pathogenic variant is well known to result in a loss of function. </plain></SENT>
<SENT sid="163" pm="."><plain>The clinically observed alteration c.5509T&gt;G (p.Trp1837Gly) (ClinVar: SCV000077040) represents a case where structural features explain the disruption of the BRCT repeat region in BRCA1. </plain></SENT>
<SENT sid="164" pm="."><plain>The C-terminal portion of BRCA1 contains a pair of BRCT repeat domains, BRCT1 and BRCT2, which are described in atomic detail, including the arrangement of amino acids that make up these domains, by 26 different crystal structures [56–59]. </plain></SENT>
<SENT sid="165" pm="."><plain>The side chain of amino acid Trp 1837 (W1837; magenta stick) is buried in the core of the BRCT2 domain surrounded by hydrophobic amino acids (green sticks), while the backbone participates in a helix involved in binding BACH1 (Figure 4) [56]. </plain></SENT>
<SENT sid="166" pm="."><plain>The alteration W1837 to G1837 (W1837G) would result in the loss of the large stabilizing hydrophobic side chain and is anticipated to be very destabilizing. </plain></SENT>
<SENT sid="167" pm="."><plain>The instability introduced by this alteration has been quantitatively calculated by computational folding algorithms which indicate it to be very destabilizing [5]. </plain></SENT>
<SENT sid="168" pm="."><plain>Indeed, E. coli expressed with in vitro mutants of p.W1837G produce an unfolded protein that was present only in inclusion bodies which could not be refolded [60]. </plain></SENT>
<SENT sid="169" pm="."><plain>In another set of biochemical and cell-based transcriptional experiments, this alteration resulted in compromised proteolysis and phosphopeptide-binding [39, 58, 59, 61]. </plain></SENT>
<SENT sid="170" pm="."><plain>Together, these functional data support the qualitative and quantitative structural observation that the variant would create a very unfavorable cavity within this domain, thereby disrupting folding and protein function. </plain></SENT>
<SENT sid="171" pm="."><plain>This example demonstrates how detailed structural analysis on publically available data can facilitate the understanding and interpretation of alterations on the function of a protein and can be supported by both computational and experimental observations. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec id="sec6"><title><text><SENT sid="172" pm="."><plain>6. </plain></SENT>
<SENT sid="173" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="174" pm="."><plain>Although cancer genetic testing has traditionally been limited to highly penetrant and well-characterized susceptibility genes, the application of multigene panels using massively parallel sequencing is steadily becoming more common in genetic cancer risk assessment due to reduced costs and increased efficiency. </plain></SENT>
<SENT sid="175" pm="."><plain>Multigene panels, in turn, tend to result in the identification of more variants per individual, the clinical significance of which needs to be assessed using multiple lines of weighted evidence. </plain></SENT>
<SENT sid="176" pm="."><plain>We present an integrated approach for assessing variants observed on hereditary breast cancer panels and believe that this improves the clinical management of patients with personal and family histories of breast cancer due to more accurate variant classification. </plain></SENT>
<SENT sid="177" pm="."><plain>Comprehensive variant assessment programs that integrate multiple lines of evidence aimed at assessing a variant's impact on protein function, fitness, and pathogenicity facilitate high-quality and efficient variant classification, providing increased benefit and reliability for patients. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="COMP_INT"><sec><title>Competing Interests</title><p>Ambry Genetics Corp. is a CLIA approved clinical genetics testing laboratory. The authors of this review are all full time paid employees of Ambry Genetics.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="178" pm="."><plain>1LaDucaH.StuenkelA. </plain></SENT>
<SENT sid="179" pm="."><plain>J.DolinskyJ. </plain></SENT>
<SENT sid="180" pm="."><plain>S.Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patientsGenetics in Medicine2014161183083710.1038/gim.2014.402-s2.0-8490888142824763289 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="181" pm="."><plain>2DalyM. </plain></SENT>
<SENT sid="182" pm="."><plain>B.AxilbundJ. </plain></SENT>
<SENT sid="183" pm="."><plain>E.BuysS.Genetic/familial high-risk assessment: breast and ovarianThe National Comprehensive Cancer Network20108562594 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="184" pm="."><plain>3National Comprehensive Cancer Network Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2016)2016, <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf">https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf</ext-link> </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="185" pm="."><plain>4MagraneM.UniProt ConsortiumUniProt knowledgebase: a hub of integrated protein dataDatabase20112011bar00910.1093/database/bar0092-s2.0-79960976768 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="186" pm="."><plain>5BermanH. </plain></SENT>
<SENT sid="187" pm="."><plain>M.WestbrookJ.FengZ.The protein data bankNucleic Acids Research200028123524210.1093/nar/28.1.2352-s2.0-003395425610592235 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="188" pm="."><plain>6LauW. </plain></SENT>
<SENT sid="189" pm="."><plain>C.LiY.LiuZ.GaoY.ZhangQ.HuenM. </plain></SENT>
<SENT sid="190" pm="."><plain>S.Structure of the human dimeric ATM kinaseCell Cycle20161581117112410.1080/15384101.2016.115836227097373 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="191" pm="."><plain>7RichardsS.AzizN.BaleS.Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine201517540542410.1038/gim.2015.302-s2.0-8492820934625741868 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="192" pm="."><plain>8RichardsC. </plain></SENT>
<SENT sid="193" pm="."><plain>S.BaleS.BellissimoD. </plain></SENT>
<SENT sid="194" pm="."><plain>B.ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007Genetics in Medicine200810429430010.1097/gim.0b013e31816b5cae2-s2.0-4214913945618414213 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="195" pm="."><plain>9TavtigianS. </plain></SENT>
<SENT sid="196" pm="."><plain>V.GreenblattM. </plain></SENT>
<SENT sid="197" pm="."><plain>S.GoldgarD. </plain></SENT>
<SENT sid="198" pm="."><plain>E.BoffettaP.Assessing pathogenicity: overview of results from the IARC unclassified genetic variants working groupHuman Mutation200829111261126410.1002/humu.209032-s2.0-5554911162618951436 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="199" pm="."><plain>10MaxwellK. </plain></SENT>
<SENT sid="200" pm="."><plain>N.HartS. </plain></SENT>
<SENT sid="201" pm="."><plain>N.VijaiJ.Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancerThe American Journal of Human Genetics201698580181710.1016/j.ajhg.2016.02.02427153395 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="202" pm="."><plain>11GonzalezK. </plain></SENT>
<SENT sid="203" pm="."><plain>D.BuzinC. </plain></SENT>
<SENT sid="204" pm="."><plain>H.NoltnerK. </plain></SENT>
<SENT sid="205" pm="."><plain>A.High frequency of de novo mutations in Li-Fraumeni syndromeJournal of Medical Genetics2009461068969310.1136/jmg.2008.0589582-s2.0-7034970575319556618 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="206" pm="."><plain>12MesterJ.EngC.Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndromeGenetics in Medicine201214981982210.1038/gim.2012.512-s2.0-8486607066022595938 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="207" pm="."><plain>13WalkerD. </plain></SENT>
<SENT sid="208" pm="."><plain>R.BondJ. </plain></SENT>
<SENT sid="209" pm="."><plain>P.TaroneR. </plain></SENT>
<SENT sid="210" pm="."><plain>E.Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional featuresOncogene199918121121810.1038/sj.onc.12022982-s2.0-00335312669926936 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="211" pm="."><plain>14LekM.KarczewskiK. </plain></SENT>
<SENT sid="212" pm="."><plain>J.MinikelE. </plain></SENT>
<SENT sid="213" pm="."><plain>V.Analysis of protein-coding genetic variation in 60,706 humansNature2016536761628529110.1038/nature1905727535533 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="214" pm="."><plain>15LiF. </plain></SENT>
<SENT sid="215" pm="."><plain>P.FraumeniJ. </plain></SENT>
<SENT sid="216" pm="."><plain>F.Jr.MulvihillJ. </plain></SENT>
<SENT sid="217" pm="."><plain>J.A cancer family syndrome in twenty-four kindredsCancer Research19884818535853622-s2.0-00237155953409256 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="218" pm="."><plain>16PrussD.MorrisB.HughesE.Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genesBreast Cancer Research and Treatment2014147111913210.1007/s10549-014-3065-92-s2.0-8490605644525085752 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="219" pm="."><plain>17GuidugliL.PankratzV. </plain></SENT>
<SENT sid="220" pm="."><plain>S.SinghN.A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activityCancer Research201373126527510.1158/0008-5472.CAN-12-20812-s2.0-8487199795623108138 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="221" pm="."><plain>18KaramR.WengrodJ.GardnerL. </plain></SENT>
<SENT sid="222" pm="."><plain>B.WilkinsonM. </plain></SENT>
<SENT sid="223" pm="."><plain>F.Regulation of nonsense-mediated mRNA decay: implications for physiology and diseaseBiochimica et Biophysica Acta—Gene Regulatory Mechanisms201318296-762463310.1016/j.bbagrm.2013.03.0022-s2.0-84877830445 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="224" pm="."><plain>19AnczukówO.WareM. </plain></SENT>
<SENT sid="225" pm="."><plain>D.BuissonM.Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?Human Mutation2008291657310.1002/humu.205902-s2.0-3814905490617694537 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="226" pm="."><plain>20JianX.BoerwinkleE.LiuX.In silico tools for splicing defect prediction: a survey from the viewpoint of end usersGenetics in Medicine201416749750310.1038/gim.2013.1762-s2.0-8490375221324263461 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="227" pm="."><plain>21HoudayerC.Caux-MoncoutierV.KriegerS.Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variantsHuman Mutation20123381228123810.1002/humu.221012-s2.0-8486387300622505045 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="228" pm="."><plain>22VreeswijkM. </plain></SENT>
<SENT sid="229" pm="."><plain>P. </plain></SENT>
<SENT sid="230" pm="."><plain>G.KraanJ. </plain></SENT>
<SENT sid="231" pm="."><plain>N.van der KliftH. </plain></SENT>
<SENT sid="232" pm="."><plain>M.Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programsHuman Mutation200930110711410.1002/humu.208112-s2.0-5834908895718693280 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="233" pm="."><plain>23WhileyP. </plain></SENT>
<SENT sid="234" pm="."><plain>J.de la HoyaM.ThomassenM.Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testingClinical Chemistry201460234135210.1373/clinchem.2013.2106582-s2.0-8489349686324212087 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="235" pm="."><plain>24MillotG. </plain></SENT>
<SENT sid="236" pm="."><plain>A.CarvalhoM. </plain></SENT>
<SENT sid="237" pm="."><plain>A.CaputoS. </plain></SENT>
<SENT sid="238" pm="."><plain>M.A guide for functional analysis of BRCA1 variants of uncertain significanceHuman Mutation201233111526153710.1002/humu.221502-s2.0-8486748524622753008 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="239" pm="."><plain>25RansburghD. </plain></SENT>
<SENT sid="240" pm="."><plain>J. </plain></SENT>
<SENT sid="241" pm="."><plain>R.ChibaN.IshiokaC.TolandA. </plain></SENT>
<SENT sid="242" pm="."><plain>E.ParvinJ. </plain></SENT>
<SENT sid="243" pm="."><plain>D.Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombinationCancer Research201070398899510.1158/0008-5472.CAN-09-28502-s2.0-7624913182020103620 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="244" pm="."><plain>26LuC.XieM.WendlM. </plain></SENT>
<SENT sid="245" pm="."><plain>C.Patterns and functional implications of rare germline variants across 12 cancer typesNature Communications201561008610.1038/ncomms100862-s2.0-84951293785 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="246" pm="."><plain>27ScullyR.GanesanS.VlasakovaK.ChenJ.SocolovskyM.LivingstonD. </plain></SENT>
<SENT sid="247" pm="."><plain>M.Genetic analysis of BRCA1 function in a defined tumor cell lineMolecular Cell1999461093109910.1016/S1097-2765(00)80238-52-s2.0-003340082810635334 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="248" pm="."><plain>28AuW. </plain></SENT>
<SENT sid="249" pm="."><plain>W. </plain></SENT>
<SENT sid="250" pm="."><plain>Y.HendersonB. </plain></SENT>
<SENT sid="251" pm="."><plain>R.The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear fociThe Journal of Biological Chemistry200528086993700110.1074/jbc.m4088792002-s2.0-1484431479015569676 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="252" pm="."><plain>29RodriguezJ. </plain></SENT>
<SENT sid="253" pm="."><plain>A.AuW. </plain></SENT>
<SENT sid="254" pm="."><plain>W. </plain></SENT>
<SENT sid="255" pm="."><plain>Y.HendersonB. </plain></SENT>
<SENT sid="256" pm="."><plain>R.Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domainExperimental Cell Research20042931142110.1016/j.yexcr.2003.09.0272-s2.0-034732058414729053 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="257" pm="."><plain>30DrostR.BouwmanP.RottenbergS.BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistanceCancer Cell201120679780910.1016/j.ccr.2011.11.0142-s2.0-8345522969322172724 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="258" pm="."><plain>31NaipalK. </plain></SENT>
<SENT sid="259" pm="."><plain>A. </plain></SENT>
<SENT sid="260" pm="."><plain>T.VerkaikN. </plain></SENT>
<SENT sid="261" pm="."><plain>S.AmezianeN.Functional Ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatmentClinical Cancer Research201420184816482610.1158/1078-0432.CCR-14-05712-s2.0-8490791488824963051 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="262" pm="."><plain>32MonteiroA. </plain></SENT>
<SENT sid="263" pm="."><plain>N. </plain></SENT>
<SENT sid="264" pm="."><plain>A.AugustA.HanafusaH.Evidence for a transcriptional activation function of BRCA1 C-terminal regionProceedings of the National Academy of Sciences of the United States of America19969324135951359910.1073/pnas.93.24.135952-s2.0-00304741708942979 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="265" pm="."><plain>33Vallon-ChristerssonJ.CayananC.HaraldssonK.Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer familiesHuman Molecular Genetics200110435336010.1093/hmg/10.4.3532-s2.0-003586482711157798 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="266" pm="."><plain>34PhelanC. </plain></SENT>
<SENT sid="267" pm="."><plain>M.DapicV.TiceB.Classification of BRCA1 missense variants of unknown clinical significanceJournal of Medical Genetics200542213814610.1136/jmg.2004.0247112-s2.0-1344429215015689452 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="268" pm="."><plain>35CarvalhoM. </plain></SENT>
<SENT sid="269" pm="."><plain>A.MarsillacS. </plain></SENT>
<SENT sid="270" pm="."><plain>M.KarchinR.Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysisCancer Research20076741494150110.1158/0008-5472.can-06-32972-s2.0-3384731448717308087 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="271" pm="."><plain>36BrzovicP. </plain></SENT>
<SENT sid="272" pm="."><plain>S.KeeffeJ. </plain></SENT>
<SENT sid="273" pm="."><plain>R.NishikawaH.Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complexProceedings of the National Academy of Sciences of the United States of America2003100105646565110.1073/pnas.08360541002-s2.0-003761080112732733 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="274" pm="."><plain>37MorrisJ. </plain></SENT>
<SENT sid="275" pm="."><plain>R.PangonL.BoutellC.KatagiriT.KeepN. </plain></SENT>
<SENT sid="276" pm="."><plain>H.SolomonE.Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibilityHuman Molecular Genetics200615459960610.1093/hmg/ddi4762-s2.0-3214446313116403807 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="277" pm="."><plain>38SouthS. </plain></SENT>
<SENT sid="278" pm="."><plain>T.LeeC.LambA. </plain></SENT>
<SENT sid="279" pm="."><plain>N.ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013Genetics in Medicine2013151190190924071793 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="280" pm="."><plain>39LeeM. </plain></SENT>
<SENT sid="281" pm="."><plain>S.GreenR.MarsillacS. </plain></SENT>
<SENT sid="282" pm="."><plain>M.Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assaysCancer Research201070124880489010.1158/0008-5472.CAN-09-45632-s2.0-7795379646320516115 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="283" pm="."><plain>40KallioniemiA.KallioniemiO.-P.SudarD.Comparative genomic hybridization for molecular cytogenetic analysis of solid tumorsScience1992258508381882110.1126/science.13596412-s2.0-00264953641359641 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="284" pm="."><plain>41PinkelD.AlbertsonD. </plain></SENT>
<SENT sid="285" pm="."><plain>G.Array comparative genomic hybridization and its applications in cancerNature Genetics2005376, supplementS11S1710.1038/ng15692-s2.0-2004437576315920524 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="286" pm="."><plain>42SaillourY.CosséeM.LeturcqF.Detection of exonic copy-number changes using a highly efficient oligonucleotide-based comparative genomic hybridization-array methodHuman Mutation20082991083109010.1002/humu.208292-s2.0-5154911077618683213 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="287" pm="."><plain>43StaafJ.TörngrenT.RambechE.Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH)Human Mutation200829455556410.1002/humu.206782-s2.0-4204908401518330910 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="288" pm="."><plain>44PetersonT. </plain></SENT>
<SENT sid="289" pm="."><plain>A.DoughtyE.KannM. </plain></SENT>
<SENT sid="290" pm="."><plain>G.Towards precision medicine: advances in computational approaches for the analysis of human variantsJournal of Molecular Biology2013425214047406310.1016/j.jmb.2013.08.0082-s2.0-8488531000823962656 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="291" pm="."><plain>45ChoiY.SimsG. </plain></SENT>
<SENT sid="292" pm="."><plain>E.MurphyS.MillerJ. </plain></SENT>
<SENT sid="293" pm="."><plain>R.ChanA. </plain></SENT>
<SENT sid="294" pm="."><plain>P.Predicting the functional effect of amino acid substitutions and indelsPLoS ONE2012710e4668810.1371/journal.pone.00466882-s2.0-84867301515 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="295" pm="."><plain>46SteflS.NishiH.PetukhM.PanchenkoA. </plain></SENT>
<SENT sid="296" pm="."><plain>R.AlexovE.Molecular mechanisms of disease-causing missense mutationsJournal of Molecular Biology2013425213919393610.1016/j.jmb.2013.07.0142-s2.0-8488518446623871686 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="297" pm="."><plain>47KucukkalT. </plain></SENT>
<SENT sid="298" pm="."><plain>G.YangY.ChapmanS. </plain></SENT>
<SENT sid="299" pm="."><plain>C.CaoW.AlexovE.Computational and experimental approaches to reveal the effects of single nucleotide polymorphisms with respect to disease diagnosticsInternational Journal of Molecular Sciences20141569670971710.3390/ijms150696702-s2.0-8490177111724886813 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="300" pm="."><plain>48KronckeB. </plain></SENT>
<SENT sid="301" pm="."><plain>M.VanoyeC. </plain></SENT>
<SENT sid="302" pm="."><plain>G.MeilerJ.GeorgeA. </plain></SENT>
<SENT sid="303" pm="."><plain>L.Jr.SandersC. </plain></SENT>
<SENT sid="304" pm="."><plain>R.Personalized biochemistry and biophysicsBiochemistry201554162551255910.1021/acs.biochem.5b001892-s2.0-8492865730925856502 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="305" pm="."><plain>49ReumersJ.SchymkowitzJ.RousseauF.Using structural bioinformatics to investigate the impact of non synonymous SNPs and disease mutations: scope and limitationsBMC Bioinformatics200910supplement 8, article S910.1186/1471-2105-10-s8-s92-s2.0-69549108301 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="306" pm="."><plain>50CasadioR.VassuraM.TiwariS.FariselliP.Luigi MartelliP.Correlating disease-related mutations to their effect on protein stability: a large-scale analysis of the human proteomeHuman Mutation201132101161117010.1002/humu.215552-s2.0-8005304756021853506 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="307" pm="."><plain>51PiresD. </plain></SENT>
<SENT sid="308" pm="."><plain>E. </plain></SENT>
<SENT sid="309" pm="."><plain>V.ChenJ.BlundellT. </plain></SENT>
<SENT sid="310" pm="."><plain>L.AscherD. </plain></SENT>
<SENT sid="311" pm="."><plain>B. In silico functional dissection of saturation mutagenesis: interpreting the relationship between phenotypes and changes in protein stability, interactions and activityScientific Reports201661984810.1038/srep198482-s2.0-84955485448 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="312" pm="."><plain>52KarchinR.AgarwalM.SaliA.CouchF.BeattieM. </plain></SENT>
<SENT sid="313" pm="."><plain>S.Classifying variants of undetermined significance in BRCA2 with protein likelihood ratiosCancer Informatics200862032162-s2.0-4964908789719043619 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="314" pm="."><plain>53YeeA. </plain></SENT>
<SENT sid="315" pm="."><plain>A.SavchenkoA.IgnachenkoA.NMR and X-ray crystallography, complementary tools in structural proteomics of small proteinsJournal of the American Chemical Society200512747165121651710.1021/ja0535652-s2.0-2844449112216305238 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="316" pm="."><plain>54FinnR. </plain></SENT>
<SENT sid="317" pm="."><plain>D.CoggillP.EberhardtR. </plain></SENT>
<SENT sid="318" pm="."><plain>Y.The Pfam protein families database: towards a more sustainable futureNucleic Acids Research2016441D279D28510.1093/nar/gkv134426673716 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="319" pm="."><plain>55HunterS.ApweilerR.AttwoodT. </plain></SENT>
<SENT sid="320" pm="."><plain>K.InterPro: the integrative protein signature databaseNucleic Acids Research2009371D211D21510.1093/nar/gkn7852-s2.0-5814920323118940856 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="321" pm="."><plain>56ClappertonJ. </plain></SENT>
<SENT sid="322" pm="."><plain>A.MankeI. </plain></SENT>
<SENT sid="323" pm="."><plain>A.LoweryD. </plain></SENT>
<SENT sid="324" pm="."><plain>M.Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancerNature Structural &amp; Molecular Biology200411651251810.1038/nsmb7752-s2.0-2542489188 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="325" pm="."><plain>57ClarkS. </plain></SENT>
<SENT sid="326" pm="."><plain>L.RodriguezA. </plain></SENT>
<SENT sid="327" pm="."><plain>M.SnyderR. </plain></SENT>
<SENT sid="328" pm="."><plain>R.HankinsG. </plain></SENT>
<SENT sid="329" pm="."><plain>D. </plain></SENT>
<SENT sid="330" pm="."><plain>V.BoehningD.Structure-function of the tumor suppressor BRCA1Computational and Structural Biotechnology Journal2012111810.5936/csbj.2012040052-s2.0-84888854732 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="331" pm="."><plain>58WilliamsR. </plain></SENT>
<SENT sid="332" pm="."><plain>S.GreenR.GloverJ. </plain></SENT>
<SENT sid="333" pm="."><plain>N. </plain></SENT>
<SENT sid="334" pm="."><plain>M.Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1Nature Structural Biology200181083884210.1038/nsb1001-8382-s2.0-003480945611573086 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="335" pm="."><plain>59WilliamsR. </plain></SENT>
<SENT sid="336" pm="."><plain>S.LeeM. </plain></SENT>
<SENT sid="337" pm="."><plain>S.HauD. </plain></SENT>
<SENT sid="338" pm="."><plain>D.GloverJ. </plain></SENT>
<SENT sid="339" pm="."><plain>N. </plain></SENT>
<SENT sid="340" pm="."><plain>M.Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1Nature Structural &amp; Molecular Biology200411651952510.1038/nsmb7762-s2.0-2542490186 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="341" pm="."><plain>60RowlingP. </plain></SENT>
<SENT sid="342" pm="."><plain>J. </plain></SENT>
<SENT sid="343" pm="."><plain>E.CookR.ItzhakiL. </plain></SENT>
<SENT sid="344" pm="."><plain>S.Toward classification of BRCA1 missense variants using a biophysical approachThe Journal of Biological Chemistry201028526200802008710.1074/jbc.m109.0889222-s2.0-7795375642820378548 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="345" pm="."><plain>61GloverJ. </plain></SENT>
<SENT sid="346" pm="."><plain>N. </plain></SENT>
<SENT sid="347" pm="."><plain>M.Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domainFamilial Cancer200651899310.1007/s10689-005-2579-z2-s2.0-3364487946816528612 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="348" pm="."><plain>An integrated approach for variant classification. </plain></SENT>
<SENT sid="349" pm="."><plain>Lines of evidence such as structural function, RNA studies, and functional studies assess the functional impact on the mRNA and protein. </plain></SENT>
<SENT sid="350" pm="."><plain>Cooccurrence, segregation, case-control studies, and the observed phenotype in variant carriers reflect the pathogenicity of a variant. </plain></SENT>
<SENT sid="351" pm="."><plain>Population frequency, in silico models, and evolutionary conservation assess fitness of the amino acid or nucleotide position. </plain></SENT>
</text></p></caption><graphic xlink:href="IJBC2016-2469523.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="352" pm="."><plain>Workflow of a functional lab for the evaluation of VUS. </plain></SENT>
</text></p></caption><graphic xlink:href="IJBC2016-2469523.002"/></fig></SecTag><SecTag type="FIG"><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="353" pm="."><plain>Identification of tandem duplication insertion breakpoints spanning BRCA1 exon 11, using paired-end sequencing. </plain></SENT>
<SENT sid="354" pm="."><plain>(a) Mapped read pairs in the wrong orientation indicate a tandem duplication. </plain></SENT>
<SENT sid="355" pm="."><plain>(b) Ambry's breakpoint detection tools can identify clusters of read pairs with soft clipping which indicate rearrangement breakpoints. </plain></SENT>
</text></p></caption><graphic xlink:href="IJBC2016-2469523.003"/></fig></SecTag><SecTag type="FIG"><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="356" pm="."><plain>The structure of BRCA1 p.Trp1837 (shown in magenta with sticks) in the BRCA-BRCT domain (PDB: 1T15 [6]). </plain></SENT>
<SENT sid="357" pm="."><plain>Nearby hydrophobic amino acids sidechains from residue 1837 are shown as sticks. </plain></SENT>
<SENT sid="358" pm="."><plain>Bound BACH1 peptide is shown as teal stick. </plain></SENT>
</text></p></caption><graphic xlink:href="IJBC2016-2469523.004"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="359" pm="."><plain>Classification scheme for high penetrance autosomal dominant breast cancer genes. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>Class </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>Classification </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>Category </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>Criteria </plain></SENT>
</text></th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1"><text><SENT sid="364" pm="."><plain>5 </plain></SENT>
</text></td><td rowspan="3" align="center" colspan="1"><text><SENT sid="365" pm="."><plain>Pathogenic </plain></SENT>
</text></td><td rowspan="3" align="center" colspan="1"><text><SENT sid="366" pm="."><plain>A1 needed(stand-alone) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>(i) Alterations resulting in premature truncation (e.g., reading frame shift, nonsense) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>(ii) Other ACMG-defined mutations (i.e., initiation codon or gross deletion) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>(iii) Strong segregation with disease (LOD &gt;3 = &gt;10 meioses) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="370" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td rowspan="8" align="left" colspan="1"><text><SENT sid="371" pm="."><plain>5 </plain></SENT>
</text></td><td rowspan="8" align="center" colspan="1"><text><SENT sid="372" pm="."><plain>Pathogenic </plain></SENT>
</text></td><td rowspan="8" align="center" colspan="1"><text><SENT sid="373" pm="."><plain>B4 needed(strong) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>(i) Confirmed de novo alteration in the setting of a new disease (appropriate phenotype) in the family(ii) Significant disease association in appropriately sized case-control study(ies) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>(iii) Being detected in individuals satisfying established diagnostic criteria for classic disease without a clear mutation </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>(iv) Last nucleotide of exon </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>(v) Good segregation with disease (LOD 1.5–3 = 5–9 meioses) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>(vi) Deficient protein function in appropriate functional assay(s) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>(vii) Functionally validated splicing mutation </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>(viii) Well-characterized mutation at the same position </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>(ix) Other strong data supporting pathogenic classification (e.g., structural) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="382" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>Likely pathogenic </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>1 needed </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>(i) Alterations at the canonical donor/acceptor sites (± 1, 2) without another strong (B-level) evidence supporting pathogenicity </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="387" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td rowspan="7" align="left" colspan="1"><text><SENT sid="388" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="7" align="center" colspan="1"><text><SENT sid="389" pm="."><plain>Likely pathogenic </plain></SENT>
</text></td><td rowspan="4" align="center" colspan="1"><text><SENT sid="390" pm="."><plain>C4 needed(supportive) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>(i) Rarity in general population databases (dbSNP, ESP, 1000 Genomes, ExAC) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>(ii) In silico models in agreement (deleterious) and/or completely conserved position in appropriate species </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>(iii) Moderate segregation with disease (at least 3 informative meioses) for rare diseases </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>(iv) Other data supporting pathogenic classification (e.g., structural) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="395" pm="."><plain>3 of B </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="396" pm="."><plain>2 of B and at least 1 of C </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="397" pm="."><plain>1 of B and at least 3 of C </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="398" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="left" colspan="1"><text><SENT sid="399" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="2" align="center" colspan="1"><text><SENT sid="400" pm="."><plain>VUS </plain></SENT>
</text></td><td colspan="2" align="left" rowspan="1"><text><SENT sid="401" pm="."><plain>Insufficient or conflicting evidence </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="402" pm="."><plain>Gross duplications without strong evidence for pathogenic or benign </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="403" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>Likely benign </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>D1 needed(strong) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>(i) Intronic alteration with no splicing impact by RT-PCR analysis or another splicing assay (ii) Other strong data supporting benign classification </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="408" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td rowspan="8" align="left" colspan="1"><text><SENT sid="409" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="8" align="center" colspan="1"><text><SENT sid="410" pm="."><plain>Likely benign </plain></SENT>
</text></td><td rowspan="8" align="center" colspan="1"><text><SENT sid="411" pm="."><plain>E2 needed(supportive) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>(i) Cooccurrences with mutations in the same gene (phase unknown) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>(ii) Cooccurrences with mutations in other high penetrant genes that clearly explain a proband's phenotype </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>(iii) Subpopulation frequency in support of benign classification </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>(iv) Intact protein function observed in appropriate functional assay(s) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>(v) In silico models in agreement (benign) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>(vi) Not segregating with disease in family study (genes with incomplete penetrance) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>(vii) No disease association in small case-control study </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>(viii) Other data supporting benign classification </plain></SENT>
</text></td></tr><tr><td align="center" colspan="4" rowspan="1"><text><SENT sid="420" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td rowspan="9" align="left" colspan="1"><text><SENT sid="421" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="9" align="center" colspan="1"><text><SENT sid="422" pm="."><plain>Benign </plain></SENT>
</text></td><td rowspan="5" align="center" colspan="1"><text><SENT sid="423" pm="."><plain>F1 needed(stand-alone) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>(i) General population or subpopulation frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>(ii) Not segregating with disease in family study (genes with complete penetrance) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>(iii) Internal frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>(iv) Being seen in trans with a mutation or in homozygous state in individuals without severe disease for that gene </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>(v) No disease association in appropriately sized case-control study(ies) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="429" pm="."><plain>1 of D and at least 2 of E </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="430" pm="."><plain>2 or more of D </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="431" pm="."><plain>&gt;3 of E w/o conflicting data </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" rowspan="1"><text><SENT sid="432" pm="."><plain>&gt;4 of E w/conflicting data </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>The variant classification scheme is not intended for the interpretation of alterations complicated by epigenetic factors including genetic modifiers, multifactorial disease, or low-risk disease association alleles and may be limited in the interpretation of alterations confounded by incomplete penetrance, variable expressivity, phenocopies, and triallelic or oligogenic inheritance.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="433" pm="."><plain>Experimental structures of genes linked to breast cancer∗. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>Gene </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>Length </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>PDBs </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>Coverage (%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>ATM </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>3056 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>0.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>BARD1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>777 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>42.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>BRCA1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>1863 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>27 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>17.6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>BRCA2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>3418 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>1.6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>BRIP1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>1249 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>1.9 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>CDH1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>882 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>26.2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>CHEK2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>543 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>38 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>86.4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>MRE11A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>708 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>58.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>MUTYH </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>549 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>77.3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>NBN </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>754 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>0.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>NF1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>2839 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>22.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>PALB2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>1186 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>29.7 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>PTEN </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>403 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>92.8 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>RAD50 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>1312 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>0.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>RAD51C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>376 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>0.0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>RAD51D </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>328 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>25.3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>TP53 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>393 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>142 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>100.0 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup><italic>∗</italic></sup>Gene lengths and coverage are tabulated from the Universal Protein Resource (Uniprot) [<xref rid="B66" ref-type="bibr">4</xref>] and the Research Collaboratory for Structural Bioinformatics (RCSB) [<xref rid="B55" ref-type="bibr">5</xref>] databases. The list of genes is taken from the BreastNext panel.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
